- |||||||||| RG6129 / Roche
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors (clinicaltrials.gov) - Aug 4, 2023
P1, N=23, Terminated,
N=260 --> 23 | Trial completion date: Feb 2024 --> Jul 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2024 --> Jul 2023; The study was terminated due to program discontinuation.
- |||||||||| RG6129 / Roche
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors (clinicaltrials.gov) - Jan 17, 2023
P1, N=260, Active, not recruiting,
N=260 --> 23 | Trial completion date: Feb 2024 --> Jul 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2024 --> Jul 2023; The study was terminated due to program discontinuation. Recruiting --> Active, not recruiting | Trial completion date: Oct 2026 --> Feb 2024 | Trial primary completion date: Oct 2026 --> Feb 2024
|
